On Thursday, a bipartisan coalition of U.S. House representatives introduced a new bill aimed at lowering the cost of insulin for Americans with private health insurance. The proposed legislation would limit out-of-pocket expenses to $35 per month. This move represents a renewed effort to tackle insulin affordability, an issue that has been the subject of congressional debate for several years.

While the bill is presented as a bipartisan effort, the path to passage remains uncertain. Historically, similar proposals have faced significant hurdles in Congress. The primary point of contention has been ideological opposition from some Republican lawmakers who argue against the government intervening in the market to set price caps. Supporters of the bill, however, view the cap as a necessary measure to ensure that patients can afford life-saving medication. The introduction of this bill by a group that includes battleground Republicans suggests a strategic push to secure a legislative win on healthcare costs, though it remains to be seen if the proposal can overcome the resistance that has stalled previous attempts at reform.